Advertisement

Pharmacological Treatment of Depression in Hispanic Americans

  • Alex J. Kopelowicz
  • Humberto Marin
  • Michael W. Smith
Chapter
Part of the Issues in Children's and Families' Lives book series (IICL, volume 8)

Personal Journey: Alex J. Kopelowicz

My personal journey began with my family’s emigration from Argentina when I was three years old. My earliest memories are as a four year old attending nursery school. Although those early school years were generally fun, I remember feeling embarrassed and frustrated during the first few weeks of school because I could not speak English with my classmates. In my house, only Spanish was spoken (my father was bilingual but my mother was not). Soon after I learned to speak English, I refused to speak Spanish at home but retained a good working knowledge of it because my parents spoke to me only in Spanish (they still do). That working knowledge came in handy years later when, after finishing my residency in psychiatry, I decided to work in a community mental health center located in a Hispanic neighborhood of Los Angeles.

My first experience with mental illness occurred many years earlier. I was 11 when a close friend of my mother’s from Argentina...

Keywords

Depressive Symptom Antidepressant Medication Poor Metabolizers Grapefruit Juice Depression Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Agundez, J. A., Ledesma, M. C., Ladero, J. M., & Benitez, J. (1995). Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clinical Pharmaclogical Therapeutics, 57(3), 265–269.CrossRefGoogle Scholar
  2. Alonso, M., Val, E., & Rapaport, M. H. (1997). An open-label study of SSRI treatment in depressed Hispanic and non-Hispanic women. Journal of Clinical Psychiatry, 58(1), 31.PubMedCrossRefGoogle Scholar
  3. American Psychiatric Association. (2000). Practice guideline for the treatment of patients with major depressive disorder (revision). American Journal of Psychiatry, 157(4, Suppl.), 1–49.Google Scholar
  4. Arias, T. D., Inaba, T., Cooke, R. G., & Jorge, L. F. (1988). A preliminary note on the transient polymorphic oxidation of sparteine in the Ngawbe Guaymi Amerindians: A case of genetic divergence with tentative phylogenetic time frame for the pathway. Clinical Pharmacological Therapeutics, 44(3), 343–352.CrossRefGoogle Scholar
  5. Bertoni, B., Budowle, B., Sans, M., Barton, S. A., & Chakraborty, R. (2003). Admixture in Hispanics: Distribution of ancestral population contributions in the Continental United States. Human Biology, 75(1), 1–11.PubMedCrossRefGoogle Scholar
  6. Bhardwaj, R. K., Glaeser, H., Becquemont, L., Klotz, U., Gupta, S. K., & Fromm, M. F. (2002). Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. Journal of Pharmacological Experimental Therapeutics, 302(2), 645–650.CrossRefGoogle Scholar
  7. Black, S. A. (1999). Increased health burden associated with comorbid depression in older diabetic Mexican Americans. Results from the Hispanic Established Population for the Epidemiologic Study of the Elderly survey. Diabetes Care, 22(1), 56–64.PubMedCrossRefGoogle Scholar
  8. Black, S. A., Goodwin, J. S., & Markides, K. S. (1998). The association between chronic diseases and depressive symptomatology in older Mexican Americans. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 53(3), M188–194.PubMedCrossRefGoogle Scholar
  9. Black, S. A., & Markides, K. S. (1999). Depressive symptoms and mortality in older Mexican Americans. Annals of Epidemiology, 9(1), 45–52.PubMedCrossRefGoogle Scholar
  10. Branch, R. A., Salih, S. Y., & Homeida, M. (1978). Racial differences in drug metabolizing ability: A study with antipyrine in the Sudan. Clinical Pharmacological Therapeutics, 24(3), 283–286.Google Scholar
  11. Casner, P. R., & Guerra, L. G. (1992). Purchasing prescription medication in Mexico without a prescription. The experience at the border. Western Journal of Medicine, 156(5), 512–516.PubMedGoogle Scholar
  12. Castaneda-Hernandez, G., Hoyo-Vadillo, C., Palma-Aguirre, J. A., & Flores-Murrieta, F. J. (1993). Pharmacokinetics of oral nifedipine in different populations. Journal of Clinical Pharmacology, 33(2), 140–145.PubMedGoogle Scholar
  13. Cooper, L. A., Gonzales, J. J., Gallo, J. J., Rost, K. M., Meredith, L. S., Rubenstein, L. V., et al. (2003). The acceptability of treatment for depression among African-American, Hispanic, and white primary care patients. Medical Care, 41(4), 479–489.PubMedGoogle Scholar
  14. Crystal, S., Sambamoorthi, U., Walkup, J. T., & Akincigil, A. (2003). Diagnosis and treatment of depression in the elderly Medicare population: Predictors, disparities, and trends. Journal of the American Geriatric Society, 51(12), 1718–1728.CrossRefGoogle Scholar
  15. Currier, M. B., Molina, G., & Kato, M. (2004). Citalopram treatment of major depressive disorder in Hispanic HIV and AIDS patients: A prospective study. Psychosomatics, 45(3), 210–216.PubMedCrossRefGoogle Scholar
  16. Dwight-Johnson, M., Sherbourne, C. D., Liao, D., & Wells, K. B. (2000). Treatment preferences among depressed primary care patients. Journal of General Internal Medicine, 15(8), 527–534.PubMedCrossRefGoogle Scholar
  17. Escobar, J. I., & Tuason, V. B. (1980). Antidepressant agents—A cross-cultural study. Psychopharmacology Bulletin, 16(3), 49–52.PubMedGoogle Scholar
  18. Escobedo, L. G., Kirch, D. G., & Anda, R. F. (1996). Depression and smoking initiation among US Latinos. Addiction, 91(1), 113–119.PubMedCrossRefGoogle Scholar
  19. Ferrando, S. J., Rabkin, J. G., de Moore, G. M., & Rabkin, R. (1999). Antidepressant treatment of depression in HIV-seropositive women. Journal of Clinical Psychiatry, 60(11), 741–746.PubMedCrossRefGoogle Scholar
  20. Fugh-Berman, A., & Myers, A. (2004). Citrus aurantium, an ingredient of dietary supplements marketed for weight loss: current status of clinical and basic research. Experimental Biological Medicine (Maywood), 229(8), 698–704.Google Scholar
  21. Gonzalez, H. M., Hinton, L., Ortiz, T., & Haan, M. N. (2006). Antidepressant class and dosing among older Mexican Americans: Application of geropsychiatric treatment guidelines. American Journal of Geriatric Psychiatry, 14(1), 79–83.PubMedCrossRefGoogle Scholar
  22. Gonzalez, H. M., Romero, E. M., Peregrina, A. A., de, J. C. T., Escobar-Islas, E., Lozano, F., et al. (2003). CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans. Journal of Clinical Pharmacology, 43(11), 1211–1215.PubMedCrossRefGoogle Scholar
  23. Guarnaccia, P. J., & Parra, P. (1996). Ethnicity, social status, and families' experiences of caring for a mentally ill family member. Community Mental Health Journal, 32(3), 243–260.PubMedCrossRefGoogle Scholar
  24. Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., Gentry, W. B., Cui, Y., et al. (2002). Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clinical Pharmacological Therapeutics, 72(3), 276–287.CrossRefGoogle Scholar
  25. Guy, W. (1976). ECDEU Assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, (ADM) 76–338.Google Scholar
  26. Hernandez Robles, M., Ramirez Enriquez, C., Gonzalez Diaz, S. N., Canseco Gonzalez, C., Arias Cruz, A., & del Castillo, O. (2002). [Psychological profile of the pediatric asthma patient]. Revista de Alergia Mexicana, 49(1), 11–15.Google Scholar
  27. Hoyo-Vadillo, C., Castaneda-Hernandez, G., Herrera, J. E., Vidal-Garate, J., Moreno-Ramos, A., Chavez, F., et al. (1989). Pharmacokinetics of nifedipine slow release tablet in Mexican subjects: Further evidence for an oxidation polymorphism. Journal of Clinical Pharmacology, 29(9), 816–820.PubMedGoogle Scholar
  28. Hunt, L. M., Jordan, B., Irwin, S., & Browner, C. H. (1989). Compliance and the patient's perspective: Controlling symptoms in everyday life. Culture, Medicine and Psychiatry, 13(3), 315–334.PubMedCrossRefGoogle Scholar
  29. Jackson-Triche, M. E., Greer Sullivan, J., Wells, K. B., Rogers, W., Camp, P., & Mazel, R. (2000). Depression and health-related quality of life in ethnic minorities seeking care in general medical settings. Journal of Affective Disorders, 58(2), 89–97.PubMedCrossRefGoogle Scholar
  30. Kinirons, M. T., Lang, C. C., He, H. B., Ghebreselasie, K., Shay, S., Robin, D. W., et al. (1996). Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: Ethnicity and CYP3A activity. British Journal of Clinical Pharmacology, 41(1), 69–72.PubMedCrossRefGoogle Scholar
  31. Kinzie, J. D., Leung, P., Boehnlein, J. K., & Fleck, J. (1987). Antidepressant blood levels in Southeast Asians. Clinical and cultural implications. Journal of Nervous and Mental Disease, 175(8), 480–485.PubMedCrossRefGoogle Scholar
  32. Lefebvre, T., Foster, B. C., Drouin, C. E., Krantis, A., Livesey, J. F., & Jordan, S. A. (2004). In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. Journal of Pharmacy and Pharmaceutical Sciences, 7(2), 265–273.PubMedGoogle Scholar
  33. Lin, K. M., Poland, R. E., & Anderson, D. (1995). Psychopharmacology, ethnicity and culture. Transcultural Psychiatric Research Review, 32(1), 3–40.CrossRefGoogle Scholar
  34. Liu, G. T. (1991). Effects of some compounds isolated from Chinese medicinal herbs on hepatic microsomal cytochrome P-450 and their potential biological consequences. Drug Metabolism Review, 23(3–4), 439–465.CrossRefGoogle Scholar
  35. Llerena, A., Herraiz, A. G., Cobaleda, J., Johansson, I., & Dahl, M. L. (1993). Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clinical Pharmacological Therapeutics, 54(6), 606–611.CrossRefGoogle Scholar
  36. Lloyd, C. E., & Brown, F. J. (2002). Depression and diabetes. Current Womens Health Reports, 2(3), 188–193.Google Scholar
  37. Luo, H. R., Poland, R. E., Lin, K. M., & Wan, Y. J. (2006). Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study. Clinical Pharmacological Therapeutics, 80(1), 33–40.CrossRefGoogle Scholar
  38. Lustman, P. J., Griffith, L. S., Clouse, R. E., & Cryer, P. E. (1986). Psychiatric illness in diabetes mellitus. Relationship to symptoms and glucose control. Journal of Nervous and Mental Disease, 174(12), 736–742.PubMedCrossRefGoogle Scholar
  39. Markowitz, J. C., Spielman, L. A., Sullivan, M., & Fishman, B. (2000). An exploratory study of ethnicity and psychotherapy outcome among HIV-positive patients with depressive symptoms. Journal of Psychotherapy Practice and Research, 9(4), 226–231.PubMedGoogle Scholar
  40. Mendoza, R., Smith, M.W., Poland, R.E., Lin, K.M., & Strickland, T.L. (1991). Ethnic psychopharmacology: The Hispanic and Native American perspective. Psychopharmacological Bulletin, 27(4), 449–461.Google Scholar
  41. Mendoza, R., Wan, Y. J., Poland, R. E., Smith, M., Zheng, Y., Berman, N., et al. (2001). CYP2D6 polymorphism in a Mexican American population. Clinical Pharmacological Therapeutics, 70(6), 552–560.CrossRefGoogle Scholar
  42. Miranda, J., Chung, J. Y., Green, B. L., Krupnick, J., Siddique, J., Revicki, D. A., et al. (2003). Treating depression in predominantly low-income young minority women: A randomized controlled trial. Journal of the American Medical Association, 290(1), 57–65.PubMedCrossRefGoogle Scholar
  43. Miranda, J., & Cooper, L. A. (2004). Disparities in care for depression among primary care patients. Journal of General Internal Medicine, 19(2), 120–126.PubMedCrossRefGoogle Scholar
  44. Miranda, J., Duan, N., Sherbourne, C., Schoenbaum, M., Lagomasino, I., Jackson-Triche, M., et al. (2003). Improving care for minorities: can quality improvement interventions improve care and outcomes for depressed minorities? Results of a randomized, controlled trial. Health Services Research, 38(2), 613–630.PubMedCrossRefGoogle Scholar
  45. Mishler, E. G. (1984). The discourse of medicine: dialectics of medical interviews. Norwood, NJ: Ablex Publishing Corporation.Google Scholar
  46. Palma-Aguirre, J. A., Nava Rangel, J., Hoyo-Vadillo, C., Girard-Cuesy, M. E., Castaneda-Hernandez, G., Arteaga-Granados, E., et al. (1994). Influence of Mexican diet on nifedipine pharmacodynamics in healthy volunteers. Proceedings of the Western Pharmacological Society, 37, 85–86.Google Scholar
  47. Physicians’ Desk Reference: PDR. (2005). Oradell, N.J.: Medical Economics Co.Google Scholar
  48. Piscitelli, S. C., Burstein, A. H., Chaitt, D., Alfaro, R. M., & Falloon, J. (2000). Indinavir concentrations and St John's wort. Lancet, 355(9203), 547–548.PubMedCrossRefGoogle Scholar
  49. Pollock, B. G., Perel, J. M., Kirshner, M., Altieri, L. P., Yeager, A. L., & Reynolds, C. F., 3rd. (1991). S-mephenytoin 4-hydroxylation in older Americans. European Journal of Clinical Pharmacology, 40(6), 609–611.PubMedGoogle Scholar
  50. Rashid, T. J., Martin, U., Clarke, H., Waller, D. G., Renwick, A. G., & George, C. F. (1995). Factors affecting the absolute bioavailability of nifedipine. British Journal of Clinical Pharmacology, 40(1), 51–58.PubMedGoogle Scholar
  51. Richardson, L. P., DiGiuseppe, D., Garrison, M., & Christakis, D. A. (2003). Depression in Medicaid-covered youth: Differences by race and ethnicity. Archives of Pediatric and Adolescent Medicine, 157(10), 984–989.CrossRefGoogle Scholar
  52. Sachse, C., Brockmoller, J., Bauer, S., & Roots, I. (1999). Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. British Journal of Clinical Pharmacology, 47(4), 445–449.PubMedCrossRefGoogle Scholar
  53. Sackett, D. L., & Haynes, R. B. (1976). Compliance with therapeutic regimens. Baltimore, MD: Johns Hopkins University Press.Google Scholar
  54. Sanchez-Lacay, J. A., Lewis-Fernandez, R., Goetz, D., Blanco, C., Salman, E., Davies, S., et al. (2001). Open trial of nefazodone among Hispanics with major depression: Efficacy, tolerability, and adherence issues. Depression and Anxiety, 13(3), 118–124.PubMedCrossRefGoogle Scholar
  55. Silver, B., Poland, R. E., & Lin, K. M. (1993). Ethnicity and the pharmacology of tricyclic antidepressants. In K. M. Lin, R. E. Poland, & G. Nakasaki (Eds.), Psychopharmacology and psychobiology of ethnicity (pp. 61–89). Washington, DC: American Psychiatric Association.Google Scholar
  56. Sirey, J. A., Meyers, B. S., Bruce, M. L., Alexopoulos, G. S., Perlick, D. A., & Raue, P. (1999). Predictors of antidepressant prescription and early use among depressed outpatients. American Journal of Psychiatry, 156(5), 690–696.PubMedGoogle Scholar
  57. Skaer, T. L., Sclar, D. A., Robison, L. M., & Galin, R. S. (2000). Trends in the rate of depressive illness and use of antidepressant pharmacotherapy by ethnicity/race: An assessment of office-based visits in the United States, 1992–1997. Clinical Therapeutics, 22(12), 1575–1589.PubMedCrossRefGoogle Scholar
  58. Sleath, B., Rubin, R. H., & Wurst, K. (2003). The influence of Hispanic ethnicity on patients' expression of complaints about and problems with adherence to antidepressant therapy. Clinical Therapeutics, 25(6), 1739–1749.PubMedCrossRefGoogle Scholar
  59. Smith, M., Lin, K. M., & Mendoza, R. (1993). “Non-biological” issues affecting psychopharmacotherapy: Cultural considerations. In K. M. Lin, R. E. Poland, & G. Nakasaki (Eds.), Psychopharmacology and psychobiology of ethnicity (pp. 37–60). Washington, DC: American Psychiatric Association.Google Scholar
  60. Van der Does, F. E., De Neeling, J. N., Snoek, F. J., Kostense, P. J., Grootenhuis, P. A., Bouter, L. M., et al. (1996). Symptoms and well-being in relation to glycemic control in type II diabetes. Diabetes Care, 19(3), 204–210.PubMedCrossRefGoogle Scholar
  61. van Manen, J. G., Bindels, P. J., Dekker, F. W., IJzermans, C.J.,, van der Zee, J. S., & Schade, E. (2002). Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax, 57(5), 412–416.PubMedCrossRefGoogle Scholar
  62. Vargas-Alarcon, G., Garcia, A., Bahena, S., Melin-Aldana, H., Andrade, F., Ibanez-de-Kasep, G., et al. (1994). HLA-B alleles and complotypes in Mexican patients with seronegative spondyloarthropathies. Annals of Rheumatic Disorders, 53(11), 755–758.CrossRefGoogle Scholar
  63. Varhe, A., Olkkola, K. T., & Neuvonen, P. J. (1994). Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clinical Pharmacological Therapeutics, 56(6 Pt 1), 601–607.CrossRefGoogle Scholar
  64. Virnig, B., Huang, Z., Lurie, N., Musgrave, D., McBean, A. M., & Dowd, B. (2004). Does Medicare managed care provide equal treatment for mental illness across races? Archives of General Psychiatry, 61(2), 201–205.PubMedCrossRefGoogle Scholar
  65. Wagner, G. J., Maguen, S., & Rabkin, J. G. (1998). Ethnic differences in response to fluoxetine in a controlled trial with depressed HIV-positive patients. Psychiatric Services, 49(2), 239–240.PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • Alex J. Kopelowicz
    • 1
  • Humberto Marin
    • 1
  • Michael W. Smith
    • 1
  1. 1.San Fernando Mental Health CenterGranada Hills

Personalised recommendations